Literature DB >> 1605616

Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.

M Hikida1, K Kawashima, K Nishiki, Y Furukawa, K Nishizawa, I Saito, S Kuwao.   

Abstract

LJC 10,627 is a new parenteral carbapenem antibiotic. LJC 10,627 stability against human renal dehydropeptidase-I was compared with that of imipenem. Hydrolysis of this compound was not detectable by spectrophotometrical assay. Even after a 2-h incubation of antibiotics with this enzyme at 30 degrees C, the concentration of LJC 10,627 remained at 92.3% of the initial concentration, whereas imipenem completely disappeared. Thus, it was found that this compound was highly stable against human renal dehydropeptidase-I. Furthermore, LJC 10,627 had a low affinity for this enzyme, as indicated by the high Ki value (0.38 mM).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605616      PMCID: PMC188463          DOI: 10.1128/AAC.36.2.481

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  A spectrophotometric assay of beta-lactamase action on penicillins.

Authors:  S G Waley
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

Review 4.  In vitro and pharmacokinetic properties of the carbapenems.

Authors:  R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.

Authors:  J Birnbaum; F M Kahan; H Kropp; J S MacDonald
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

7.  In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.

Authors:  S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  8 in total
  9 in total

1.  In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae.

Authors:  Reiko Kobayashi; Mami Konomi; Keiko Hasegawa; Miyuki Morozumi; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; Y Takiguchi; S Matsumoto; M Minamoto; Y Niida; M Yokokawa; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

6.  Interactions of biapenem with active-site serine and metallo-beta-lactamases.

Authors:  A Felici; M Perilli; B Segatore; N Franceschini; D Setacci; A Oratore; S Stefani; M Galleni; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats.

Authors:  M Hikida; Y Masukawa; K Nishiki; N Inomata
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem.

Authors:  Y Asahi; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

9.  PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.

Authors:  Gaku Akashita; Yuto Hosaka; Toru Noda; Kazuya Isoda; Tsutomu Shimada; Kazuki Sawamoto; Ken-Ichi Miyamoto; Takumi Taniguchi; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2015-11-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.